glp-1 receptor agonist type 1 diabetes randomized trial Efficacy and safety of LY3298176, a novel dual GIP and agonist, in patients with 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 GLP-1 receptor agonists show promise

Offer valid for new BetterHelp users only

10.1093/ndt/gfad009 86 Sanchez-GarridoM

Concentration (start) Volume (start) = Concentration (final) Volume (final) Purity & Documentation Data Sheet (273 KB) SDS (252 KB) English - EN (252 KB) Franais - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Espaol - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB) Handling Instructions (2659 KB) References Complete Stock Solution Preparation Table Please refer to the solubility information to select the appropriate solvent

doi: 10.1152/ajpgi.00190.2017 35 GedulinBRRinkTJYoungAA

has served on scientific advisory panels and/or speaker's bureaus and served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Fractyl, Gubra, Merck Sharp & Dohme, Novo Nordisk, Sanofi and Zealand Pharma